Drug Overview

Dalpiciclib is a precise, oral targeted therapy medication that helps treat advanced breast cancer by slowing the rapid growth of cancer cells. Known as a “smart drug” in the class of CDK4/6 inhibitors, it works by blocking specific proteins that cancer cells rely on to divide and spread, while mostly sparing healthy cells. This makes it a key partner for hormone therapies, offering hope to patients with hormone receptor-positive breast cancers. Doctors and patients alike value its role in extending time without disease progression and improving quality of life during treatment.

Developed as SHR6390 (also called Ai Rui Kang), dalpiciclib gained approval in China in 2021 for certain breast cancer cases and continues in global clinical trials. For international patients in the US and Europe, it represents a promising option in ongoing studies at leading cancer centers. This guide provides trustworthy, easy-to-read details for both patients seeking clear answers and healthcare professionals needing quick clinical references.

Generic name: Dalpiciclib (SHR6390).
US Brand names: None available; still investigational in the United States.
Drug Class: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor; targeted anticancer therapy.
Route of Administration: Oral capsules, taken whole with water.
FDA Approval Status: Not approved by the FDA. Approved by China’s National Medical Products Administration (NMPA) for specific breast cancer indications; actively studied in Phase 3 trials worldwide.

What Is It and How Does It Work? (Mechanism of Action)

Dalpiciclib belongs to the targeted therapy family, specifically designed to interrupt the cell cycle where cancer cells go wrong. In normal cells, division follows a strict sequence called the cell cycle, with built-in brakes to prevent uncontrolled growth. Cancer cells, particularly those driven by hormones like estrogen, ignore these brakes, leading to rapid tumor spread.

At the molecular level, dalpiciclib acts with high selectivity on cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes normally bind to cyclin D proteins, which rise in response to growth signals such as estrogen receptor (ER) activation in HR-positive breast cancers. The CDK4/6-cyclin D complex then phosphorylates—adds phosphate molecules to—the retinoblastoma protein (Rb1). This phosphorylation disables Rb1’s suppressive role, releasing E2F transcription factors. E2F switches on hundreds of genes essential for DNA replication, pushing cells from the G1 growth phase into the S phase where DNA copies for division.

Dalpiciclib binds tightly to the ATP-binding pocket of CDK4/6, preventing this phosphorylation. Rb1 stays active, binding E2F and blocking gene activation. Cancer cells halt at the G1 phase, leading to senescence (permanent growth arrest), reduced expression of survival proteins like Bcl-2, and eventual cell death through apoptosis. Unlike broader chemotherapies, this precision spares most healthy cells, which have lower cyclin D dependence. Dalpiciclib also enhances anti-tumor immunity by promoting immunogenic senescence, increasing antigen presentation on tumor cells to attract T-cells. In HR-positive cancers, it synergizes with endocrine therapies by countering estrogen-induced cyclin D overexpression. Studies highlight its potency, often outperforming peers like palbociclib in binding affinity and selectivity for tumor cells.

FDA-Approved Clinical Indications

Dalpiciclib does not have FDA approval for any use. However, it holds NMPA approval in China, and strong evidence from international trials supports its role in breast cancer management.

Oncological uses (NMPA-approved in China; under investigation globally):

Combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer after progression on prior endocrine therapy.
First-line treatment with aromatase inhibitors (letrozole or anastrozole) for HR-positive, HER2-negative advanced breast cancer.
Investigational combinations for HR-positive, HER2-positive breast cancer with pyrotinib and endocrine therapy, showing early promise.

Non-oncological uses (if any):

None currently established or studied.

Dosage and Administration Protocols

Patients take dalpiciclib orally once daily, ideally at the same time each day, with or without food. Treatment follows 28-day cycles: 21 days of active dosing followed by 7 days off for recovery. Your oncologist will monitor blood counts closely to adjust as needed, ensuring safety while maximizing benefits.

Specification	Details
Standard Dose	150 mg (three 50 mg capsules) orally once daily
Frequency	Days 1–21 of each 28-day cycle; repeat cycles until disease progression or intolerance
Administration Time	Swallow capsules whole with water; no crushing or chewing
Renal Insufficiency (Mild/Moderate, CrCl ≥30 mL/min)	No dose adjustment required
Severe Renal Impairment (CrCl <30 mL/min)	Reduce to 100 mg once daily; use caution, avoid dialysis patients
Hepatic Insufficiency (Child-Pugh A)	No adjustment
Moderate Hepatic Impairment (Child-Pugh B)	Reduce to 100 mg once daily
Severe Hepatic Impairment (Child-Pugh C)	Avoid use
Dose Modifications for Toxicity	First reduction: 125 mg; second: 100 mg; discontinue if further needed
Missed Dose	Skip if less than 12 hours until next dose; do not double up

Blood tests guide adjustments, especially for neutropenia common with CDK4/6 inhibitors.

Clinical Efficacy and Research Results

Clinical trials between 2020 and 2025 demonstrate dalpiciclib’s ability to significantly delay cancer progression and improve outcomes in breast cancer patients. In the pivotal DAWNA-1 Phase 3 trial for HR-positive/HER2-negative advanced breast cancer, dalpiciclib plus fulvestrant extended median progression-free survival (PFS) to 30.6 months compared to 15.7 months with placebo plus fulvestrant (hazard ratio [HR] 0.42; p<0.0001). Objective response rates were 56% versus 29%, with disease control exceeding 90% in the combination arm.

The DAWNA-2 first-line trial mirrored these benefits, achieving PFS of 15.7 months with dalpiciclib plus letrozole/anastrozole versus 7.2 months with placebo (HR 0.42). In early-stage disease, the DAWNA-A adjuvant study reported 24-month invasive disease-free survival of 94.7% with dalpiciclib versus 90.2% with placebo alone (HR 0.56). For triple-positive (HR+/HER2+) cases, combinations with pyrotinib yielded objective response rates of 67% and median PFS of 11.3 months.

These results position dalpiciclib comparably or superior to established CDK4/6 inhibitors like palbociclib, with lower rates of treatment discontinuation (around 5-10%). Patients report better tolerance, leading to sustained quality of life gains. Ongoing overall survival data trends positive, with fewer progressions to chemotherapy, potentially adding months to life expectancy in responsive cases.

Safety Profile and Side Effects

Dalpiciclib maintains a favorable safety profile for a targeted therapy, primarily causing manageable drops in blood cell counts due to its cell cycle effects.

Common Side Effects (>10%)

Neutropenia (low neutrophils: 70-86% of patients).
Leukopenia (low white cells overall: 55-75%).
Anemia (low red blood cells: 45-60%).
Fatigue and asthenia (35-50%).
Gastrointestinal issues like nausea, diarrhea, or vomiting (25-35%).

Serious Adverse Events

Febrile neutropenia (fever with low neutrophils: <5%; requires hospitalization).
Interstitial lung disease or pneumonitis (1-2%; monitor breathing).
Hepatotoxicity (elevated liver enzymes: 5-10%).
QT interval prolongation (heart rhythm changes: rare, <2%).

No Black Box Warning applies, unlike some older cancer drugs.

Management Strategies:

For neutropenia: Pause treatment; administer granulocyte colony-stimulating factor (G-CSF) like filgrastim if ANC <500/mm³. Resume at reduced dose (125 mg, then 100 mg) once ANC recovers to ≥1000/mm³.
Nausea/diarrhea: Antiemetics (ondansetron) or antidiarrheals (loperamide); eat bland, small meals.
Fatigue: Prioritize rest, light walking, and balanced nutrition; avoid overexertion.
Any fever over 100.4°F, shortness of breath, chest pain, or yellowing skin: Contact your doctor immediately for urgent evaluation.
Routine monitoring: CBC every two weeks initially, then monthly; liver function and ECG as needed.

Research Areas

Dalpiciclib shows exciting potential in combination with immunotherapies and targeted approaches. Current trials pair it with PD-1/PD-L1 inhibitors in triple-negative breast cancer, capitalizing on CDK4/6 inhibition’s ability to boost T-cell infiltration and antigen presentation within tumors. Preliminary data indicate improved response rates when combined with CAR-T cell therapies, as it sensitizes cancer cells to immune attack by altering the tumor microenvironment.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

Complete blood count (CBC), comprehensive metabolic panel (liver/kidney function).
Electrocardiogram (ECG) for heart rhythm baseline.
Pregnancy test for all women of childbearing potential.
Confirmation of HR/HER2 status via biopsy or prior pathology.

Precautions during treatment:

Use reliable contraception (e.g., IUD, pills) during treatment and for 21 days after; it can harm a fetus.
Avoid strong CYP3A4 inhibitors (ketoconazole) or inducers (rifampin, St. John’s Wort) that alter drug levels.
Limit grapefruit juice, which boosts exposure.

“Do’s and Don’ts” list:

DO take capsules at the same time daily and stay well-hydrated.
DO report new symptoms like persistent cough, fever, or extreme tiredness promptly.
DO maintain a healthy diet rich in fruits, vegetables, and proteins to support blood counts.
DON’T crush, chew, or open capsules; swallow intact.
DON’T consume alcohol excessively or use unapproved herbal supplements.
DON’T skip scheduled blood tests or follow-up scans.

Legal Disclaimer

This guide offers general educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Dalpiciclib’s availability and use depend on local regulations and individual health factors. Always consult your oncologist or healthcare team for personalized guidance, including eligibility for clinical trials. Follow evidence-based protocols from qualified professionals.